Kodiak Sciences Q2 net loss $80.2M; winds down tarcocimab after Phase 3 DME miss

Kodiak Sciences Inc.

2023-Q2 EPS reported -$2.88

Q2 2023 net loss $80.2M ($1.53/sh) vs $90.6M ($1.74/sh) in Q2 2022.
Cash and equivalents $378.7M at June 30, 2023.
Phase 3 GLEAM and GLIMMER in DME missed primary efficacy endpoint; tarcocimab studies being wound down.
Phase 3 DAYLIGHT in wet AMD met endpoint; no cataract imbalance observed.
KSI-501 Phase 1 enrollment completed; exploring both unconjugated protein and bioconjugate forms.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kodiak Sciences Inc. reported the quarter ended June 30, 2023 results: net income $80.2 million, or $1.53 per share on both a basic and diluted basis, EPS $1.53 per share on both a basic and diluted basis.

Period: the quarter ended June 30, 2023
Net income: $80.2 million, or $1.53 per share on both a basic and diluted basis
EPS: $1.53 per share on both a basic and diluted basis
Result: reported results

Exact text from the filing

The net loss for the second quarter of 2023 was $80.2 million, or $1.53 per share on both a basic and diluted basis

View on SEC.gov

Browse all earnings releases →

Kodiak Sciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-042419

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.